Unicycive Therapeutics, Inc.
UNCYDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
UNCY Earnings Report
EPS Est: $-0.34 | FQ end 2026-06
How UNCY's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oxylanthanum Carbonate | Phase 2 | Chronic Kidney Disease Requiring Chronic Dialysis | - | Patent 2030 |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Unicycive Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Unicycive Therapeutics, Inc.'s (UNCY) pipeline across Phase 2. Its lead program is Oxylanthanum Carbonate (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Unicycive Therapeutics, Inc.'s next FDA catalyst?→
Unicycive Therapeutics, Inc.'s (UNCY) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track UNCY biotech catalysts?→
Add UNCY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Unicycive Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.